Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Previous autoradiographic studies in rats using [3H]CP55,940 have demonstrated the cannabinoid receptor to be located on the axon terminals of striatal efferent neurons projecting to the globus pallidus and substantia nigra. Because these neurons are selectively lost in Huntington's disease, a loss of [3H]CP55,940 binding is predicted in the substantia nigra of the Huntington's disease brain. We have used autoradiography to compare the binding of [3H]CP55,940 in the substantia nigra of Huntington's disease and neurologically normal brains. The results have demonstrated that cannabinoid receptors in the normal human substantia nigra are discreetly localized within the substantia nigra pars reticulata. In contrast, the Huntington's disease brains show a massive loss (97.5%) of cannabinoid receptor binding in the substantia nigra pars reticulata. These results show that in the substantia nigra of the human brain cannabinoid receptors are located on striatonigral terminals which degenerate in Huntington's disease.
Glass
M
M
Department of Pharmacology, School of Medicine, University of Auckland, New Zealand.
Faull
R L
RL
Dragunow
M
M
D000368:Aged; D000369:Aged, 80 and over; D001345:Autoradiography; D002186:Cannabinoids; D003511:Cyclohexanols; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism* / Q000473:pathology; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D017729:Presynaptic Terminals / Q000378:metabolism; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism* / Q000473:pathology
D002186:Cannabinoids; D003511:Cyclohexanols; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol